<DOC>
	<DOCNO>NCT02383771</DOCNO>
	<brief_summary>The purpose study determine proportion untreated donor platelet require fully reverse platelet inhibitory effect ticagrelor aspirin healthy person patient coronary artery disease undergo percutaneous coronary intervention ( PCI ) receive ticagrelor .</brief_summary>
	<brief_title>Reversal Anti-platelet Effects Ticagrelor</brief_title>
	<detailed_description>Reversal Anti-platelet Effects Ticagrelor : REVERSAL study The fatality stent thrombosis ( ST ) patient coronary artery disease ( CAD ) undergo percutaneous coronary intervention ( PCI ) approximately 50 % clopidogrel important anti-platelet drug prevention ST. CAD patient implant stent include bare metal stent ( BMS ) drug elute stent ( DES ) recommend receive dual anti-platelet treatment ( DAPT ) , i.e . clopidogrel along aspirin , least one year reduce incidence ST up-to-date guideline . However , due variability anti-platelet effect clopidogrel , regular dose ( 75 mg daily ) clopidogrel administer achieve enough inhibition platelet aggregation 20-30 % total patient , name clopidogrel low responsiveness ( CLR ) , morbidity thrombosis ( include ) CAD patient still 10 % . Ticagrelor , cyclopentyl-triazolo-pyrimidine , potent adenosine diphosphate ( ADP ) receptor antagonist faster onset significantly high inhibition platelet aggregation compare clopidogrel directly act P2Y12-ADP receptor platelet without process hepatic metabolism . In PLATO study , ticagrelor plus reduced remarkable incidence cardiovascular event patient acute coronary syndrome ( ACS ) without significant high incidence major bleed event compare clopidogrel plus aspirin . Surprisingly , incidence death due cardiovascular cause total fatality decrease patient ticagrelor plus aspirin compare clopidogrel plus aspirin . The result suggest benefit brought ticagrelor , highlight wide use future . Due potent anti-platelet effect ticagrelor , bleed event may occur . Additionally , face need cardiac non-cardiac operation , occurrence life-threatening bleeding event necessity emergency operation , doctor may confuse treatment patient take ticagrelor , half-life period 8-9 hour suggest importance study reversal anti-platelet effect ticagrelor . The primary objective study investigate proportion untreated donor platelet require fully reverse platelet inhibitory effect aspirin ticagrelor healthy person patient coronary artery disease undergo percutaneous coronary intervention ( PCI ) receive ticagrelor . Study Population : The investigator design two cohort study , plan enroll 32 healthy volunteer cohort 1 16 patient coronary artery disease undergo percutaneous coronary intervention ( PCI ) receive dual anti-platelet therapy ( ticagrelor 90mg bid + aspirin 100mg daily ) 7 day Cohort 1 : Randomization : A total 32 healthy volunteer plan enrol randomly divide three group : single anti-platelet treatment group ( A group , 8 32 ) , dual anti-platelet treatment group ( B group , 8 32 ) control group ( C group , 16 32 ) . 1 . Single anti-platelet treatment group : ( Ticagrelor 90mg bid ) × 7 day 2 . Dual anti-platelet treatment group : ( Ticagrelor 90mg bid + Aspirin 100mg daily ) × 7 day 3 . Control group : No anti-platelet therapy Inclusion criterion : 1 . Healthy volunteer 2 . Participants age &gt; 18 year old Exclusion criterion : 1 . Allergy intolerance aspirin ticagrelor ; 2 . Subjects high risk bleeding ( e.g . platelet count &lt; 100×10^9/L , history peptic ulcer , hemoglobin &lt; 110g/L ) ; 3 . Subjects bronchial asthma chronic obstructive pulmonary disease ; 4 . Subjects bradycardia ( e.g . sick sinus syndrome , high-grade atrioventricular block , history syncope unproved uncorrelation bradycardia ) ; 5 . Smokers ; 6 . Subjects diabetes mellitus ; 7 . Subjects plan pregnancy ; 8 . Subjects hepatic renal dysfunction ; 9 . Subjects take anti-platelet drug , non-steroidal anti-inflammatory drug proton pump inhibitor scan need take study period . Blood collection sample preparation Venous blood sample collect venipuncture two 4.5-mL draw BD vacutainer tube contain 0.105M buffered sodium citrate ( 3.2 % ) 08.00 hour morning take agent last dose study drug . Platelet-rich plasma ( PRP ) subject A group mixed increase proportion C group , one untreated subject serve control one treat subject . The proportion control platelets mixed inhibited platelet calculate base platelet number , start 10 % increase 10 % increment . So PRP B group . Test : 1 . Before take agent : 1 . ADP-induced platelet aggregation : light transmittance aggregation ( LTA ) response 5μM ADP 2 . Arachidonic acid ( AA ) -induced platelet aggregation : LTA response 1mM AA 2 . After 7-day medication : 1 . ADP-induced platelet aggregation : LTA response 5μM ADP 2 . AA-induced platelet aggregation : LTA response 1mM AA 3 . ADP-induced platelet aggregation mixed sample : LTA response 5μM ADP 4 . AA-induced platelet aggregation mixed sample : LTA response 1mM AA Primary end point : 1 . Reversal platelet inhibitory effect antiplatelet therapy Proportion untreated donor platelet require fully reverse platelet inhibitory effect antiplatelet therapy healthy volunteer Secondary end point : 1 . Inhibition platelet aggregation ( IPA ) response 5μM ADP determine light transmittance aggregometer ( LTA ) 7-day ticagrelor administration Safety issue : No Cohort 2 : A total 16 patient diagnosed coronary artery disease undergone percutaneous coronary intervention ( PCI ) receive dual anti-platelet therapy ( ticagrelor 90mg bid + aspirin 100mg daily ) 7 day plan enrolled . Inclusion Criteria : 1 . Subjects diagnose coronary artery disease undergo percutaneous coronary intervention ( PCI ) ; 2 . Subjects receive dual anti-platelet therapy ( ticagrelor 90mg bid + aspirin 100mg daily ) 7 day ; Exclusion Criteria : 1 . Subjects high risk bleeding ( e.g . platelet count &lt; 100×10^9/L , history peptic ulcer , hemoglobin &lt; 110g/L ) ; 2 . Subjects anemia ; 3 . Smokers 4 . Subjects plan pregnancy ; 5 . Subjects hepatic renal dysfunction ; 6 . Subjects take anti-platelet drug , non-steroidal anti-inflammatory drug proton pump inhibitor scan need take study period . Sample test fresh platelet save blood bank Function platelet aggregation , platelet count , pH value metabolic product ( include PO2 , PCO2 , blood glucose , lactate , bicarbonate , sodium , potassium chloride ) measure fresh platelet sample preserve blood bank 1 , 2 , 3 , 4 , 5 day respectively . Blood collection sample preparation patient Venous blood sample collect venipuncture two 4.5-mL draw BD vacutainer tube contain 0.105M buffered sodium citrate ( 3.2 % ) 08.00 hour morning take medicine . Platelet-rich plasma ( PRP ) participant mixed increase proportion extract fresh platelet sample reserve blood bank one day control treat subject . The proportion control platelets mixed inhibited platelet calculate base platelet number , start 10 % increase 10 % increment . So PRP mixed fresh platelet sample preserve four day . Test sample patient 1 . Before mixture : 1 . ADP-induced platelet aggregation : light transmittance aggregation ( LTA ) response 5μM ADP 2 . Arachidonic acid ( AA ) -induced platelet aggregation : LTA response 1mM AA 2 . After mixture : 1 . ADP-induced platelet aggregation : LTA response 5μM ADP 2 . AA-induced platelet aggregation : LTA response 1mM AA Primary end point : 1 . Reversal platelet inhibitory effect antiplatelet therapy Proportion untreated donor platelet require fully reverse platelet inhibitory effect antiplatelet therapy patient coronary artery disease undergo percutaneous coronary intervention ( PCI ) receive ticagrelor Secondary end point : 1 . Relationship function platelet aggregation time save fresh platelet . Safety issue : No</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Cohort 1 : Healthy volunteer ; Subjects age &gt; 18 year old ; Allergy intolerance aspirin ticagrelor ; Subjects high risk bleeding ( e.g . platelet count &lt; 100×10^9/L , history peptic ulcer , hemoglobin &lt; 110g/L ) ; Subjects anemia ; Subjects bronchial asthma chronic obstructive pulmonary disease ; Subjects bradycardia ( e.g . sick sinus syndrome , highgrade atrioventricular block , history syncope unproved uncorrelation bradycardia ) ; Smokers ; Subjects diabetes mellitus ; Subjects planning pregnancy ; Subjects hepatic renal dysfunction ; Subjects take antiplatelet drug , nonsteroidal antiinflammatory drug proton pump inhibitor scan need take study period . Cohort 2 : Subjects diagnose coronary artery disease undergo percutaneous coronary intervention ( PCI ) ; Subjects receive dual antiplatelet therapy ( ticagrelor 90mg bid + aspirin 100mg daily ) 7 day ; Subjects high risk bleeding ( e.g . platelet count &lt; 100×10^9/L , history peptic ulcer , hemoglobin &lt; 110g/L ) ; Subjects anemia ; Smokers Subjects plan pregnancy ; Subjects hepatic renal dysfunction ; Subjects take antiplatelet drug , nonsteroidal antiinflammatory drug proton pump inhibitor scan need take study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Peri-operative treatment</keyword>
</DOC>